Key Drivers
- Strong profitability
- Ample liquidity
- Weak cash conversion
AIAI Summary
Bio-Rad is now a margin-execution and portfolio-mix thesis—not merely a recovery story—where digital PCR and Clinical Diagnostics plus $30–$35M in savings could unlock substantial earnings leverage, but investors should wait for sustained organic growth and stronger free-cash-flow conversion before underwriting a ~40x forward P/E.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong profitability
- •Ample liquidity
- •Weak cash conversion
BIO's strong profitability, low leverage, and large investment base are tempered by weaker liquidity, modest cash conversion, and sharply elevated valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Failed $390
- •Support Test
- •Weak Momentum
BIO is weakening below its short-term average after failing near $390; watch $368–$369 support, while a reclaim of $380–$382 would improve momentum.
Volatile last-month swings between the upper-$360s and near $390
Sentiment & News
Key News Insights:
- •Margin expansion
- •Institutional buying
- •Valuation risk
Bio-Rad's strong stock momentum and margin-improvement plans support upside, but elevated valuation and weak Life Science demand warrant caution.
The outlook is cautiously positive, with execution on margins key to sustaining gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings